Allena Pharmaceuticals ALNA

$ 0.08 3.16%

Quarterly report 2022-Q2
added 08-15-2022

Allena Pharmaceuticals Balance Sheet 2011-2024 | ALNA

Annual Balance Sheet Allena Pharmaceuticals

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-29.5 M	-21.2 M	-20 M	-51.7 M	-85.1 M	-15.7 M	-62.8 M	-	-	-	-
Long Term Debt	210 K	9.85 M	5.99 M	9.98 M	5.52 M	9.41 M	3.93 M	-	-	-	-
Long Term Debt Current	317 K	291 K	498 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	10.2 M	6 M	10 M	5.84 M	106 M	99.8 M	-	-	-	-
Total Current Liabilities	15.7 M	6.12 M	10.9 M	5.76 M	7.54 M	-	-	-	-	-	-
Total Liabilities	15.9 M	16.4 M	16.9 M	15.8 M	13.4 M	109 M	105 M	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-246 M	-198 M	-165 M	-118 M	-82 M	-60.3 M	-35.8 M	-	-	-	-
Total Assets	34.8 M	38.9 M	34.1 M	65.2 M	96.2 M	49.5 M	70 M	-	-	-	-
Cash and Cash Equivalents	30 M	35 M	30 M	61.6 M	94.5 M	25.2 M	-	-	-	-	-
Book Value	18.9 M	22.6 M	17.2 M	49.5 M	82.9 M	-59.3 M	-35 M	-	-	-	-
Total Shareholders Equity	18.9 M	22.6 M	17.2 M	49.5 M	82.9 M	-59.3 M	-35 M	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Allena Pharmaceuticals

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	210 K	274 K	12.1 M	12.5 M	12.8 M	12.8 M	387 K	387 K	10.6 M	14 K	14 K	14 K	11.3 M	-	-	-	11.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	14.1 M	10.1 M	15.9 M	17.8 M	18 M	17 M	16.4 M	16.4 M	16.4 M	16.4 M	16.9 M	16.9 M	16.9 M	16.9 M	15.8 M	15.8 M	15.8 M	15.8 M	13.4 M	13.4 M	13.4 M	13.4 M	13 M	13 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-267 M	-258 M	-246 M	-236 M	-223 M	-209 M	-198 M	-198 M	-198 M	-198 M	-165 M	-165 M	-165 M	-165 M	-118 M	-118 M	-118 M	-118 M	-82 M	-82 M	-82 M	-82 M	-60.3 M	-60.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	17.8 M	21.7 M	34.8 M	43.9 M	30.3 M	40.5 M	38.9 M	38.9 M	38.9 M	38.9 M	34.1 M	34.1 M	34.1 M	34.1 M	65.2 M	65.2 M	65.2 M	65.2 M	96.2 M	96.2 M	96.2 M	96.2 M	49.5 M	49.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	6.59 M	8.9 M	30 M	40.4 M	26.7 M	36.3 M	35 M	35 M	35 M	35 M	30 M	30 M	30 M	30 M	61.6 M	61.6 M	61.6 M	61.6 M	94.5 M	94.5 M	94.5 M	94.5 M	25.2 M	25.2 M	-	-	69 M	-	-	-	26.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	3.74 M	11.6 M	18.9 M	26 M	12.3 M	23.5 M	22.6 M	22.6 M	22.6 M	22.6 M	17.2 M	17.2 M	17.2 M	17.2 M	49.5 M	49.5 M	49.5 M	49.5 M	82.9 M	82.9 M	82.9 M	82.9 M	36.4 M	36.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	3.74 M	11.6 M	18.9 M	26 M	12.3 M	23.5 M	22.6 M	22.6 M	22.6 M	22.6 M	17.2 M	17.2 M	17.2 M	17.2 M	49.5 M	49.5 M	49.5 M	49.5 M	82.9 M	82.9 M	82.9 M	82.9 M	-59.3 M	-59.3 M	-	-	-35 M	-	-	-	-20.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency